Alumis Inc.
ALMS
株式のランク
#10418
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the... Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid eye diseases; and interferon regulatory factor 5 (IRF5) to address immune dysfunction. The company was formerly known as Esker Therapeutics, Inc. and changed its name to Alumis Inc. in January 2022. Alumis Inc. was incorporated in 2021 and is headquartered in South San Francisco, California.
株価
$6.15
最終同期: 2026-10-16
時価総額
$795.38M
変化（1日）
-2.61%
変化（1年）
170.70%
国
US
取引 Alumis Inc. (ALMS)
カテゴリー
Healthcare
Alumis Inc.（ALMS）のEPS
March 2025 時点のEPS TTM: $-2.70
Alumis Inc.の最新の財務報告と株価によると、同社の現在のEPS（TTM）は$-2.70です。2023年末には、EPSは$-5.43で、2022年のEPS$-0.70と増加でした。
Alumis Inc.のEPS履歴（2021から2026まで）
各年末時点のEPS
| 年 | EPS | 変化 |
|---|---|---|
| 2026 (TTM) | $-2.70 | 8.00% |
| 2024 | $-2.50 | -53.96% |
| 2023 | $-5.43 | 675.71% |
| 2022 | $-0.70 | -65.85% |
| 2021 | $-2.05 | 0.00% |
同様の企業または競合他社のEPS
| 企業 | EPS | EPSの差 | 国 |
|---|---|---|---|
| $17.32 | -741.48% |
US
|
|
| $-7.98 | 195.56% |
US
|
|
| $-5.29 | 95.93% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -1,127.41% |
NL
|
